CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade BioMarin Pharmaceutical Inc - BMRN CFD

88.55
1.62%
Market Trading Hours* (UTC) Opens on Monday at 13:30

Mon - Fri: 13:30 - 20:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.17
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Biomarin Pharmaceutical Inc ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 90.01
Open* 89.87
1-Year Change* -8.56%
Day's Range* 88.26 - 89.93
52 wk Range 76.02-117.77
Average Volume (10 days) 1.12M
Average Volume (3 months) 35.96M
Market Cap 17.43B
P/E Ratio 120.40
Shares Outstanding 188.37M
Revenue 2.31B
EPS 0.77
Dividend (Yield %) N/A
Beta 0.32
Next Earnings Date Feb 26, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Apr 19, 2024 88.55 -0.92 -1.03% 89.47 90.03 88.13
Apr 18, 2024 90.01 0.02 0.02% 89.99 91.15 89.54
Apr 17, 2024 90.42 -0.42 -0.46% 90.84 91.41 89.87
Apr 16, 2024 90.61 0.32 0.35% 90.29 91.68 89.98
Apr 15, 2024 91.13 -0.87 -0.95% 92.00 93.30 90.90
Apr 12, 2024 92.15 1.31 1.44% 90.84 93.16 90.16
Apr 11, 2024 91.37 1.44 1.60% 89.93 91.52 89.20
Apr 10, 2024 90.08 2.27 2.59% 87.81 90.32 87.62
Apr 9, 2024 88.88 2.45 2.83% 86.43 89.11 86.43
Apr 8, 2024 87.28 1.23 1.43% 86.05 88.03 85.71
Apr 5, 2024 86.84 0.84 0.98% 86.00 87.14 85.46
Apr 4, 2024 86.79 0.59 0.68% 86.20 87.99 85.93
Apr 3, 2024 86.67 0.88 1.03% 85.79 87.65 85.29
Apr 2, 2024 86.68 1.01 1.18% 85.67 86.86 85.26
Apr 1, 2024 87.03 0.75 0.87% 86.28 87.18 86.02
Mar 28, 2024 87.27 -0.70 -0.80% 87.97 88.34 86.59
Mar 27, 2024 88.38 0.56 0.64% 87.82 88.68 87.23
Mar 26, 2024 87.63 1.17 1.35% 86.46 87.79 86.41
Mar 25, 2024 86.43 1.88 2.22% 84.55 86.91 84.30
Mar 22, 2024 85.02 1.25 1.49% 83.77 85.23 83.54

BioMarin Pharmaceutical Inc Events

Time (UTC) Country Event
Wednesday, April 24, 2024

Time (UTC)

20:00

Country

US

Event

Q1 2024 Biomarin Pharmaceutical Inc Earnings Release
Q1 2024 Biomarin Pharmaceutical Inc Earnings Release

Forecast

-

Previous

-

Time (UTC)

20:30

Country

US

Event

Q1 2024 Biomarin Pharmaceutical Inc Earnings Call
Q1 2024 Biomarin Pharmaceutical Inc Earnings Call

Forecast

-

Previous

-
Tuesday, May 21, 2024

Time (UTC)

16:00

Country

US

Event

Biomarin Pharmaceutical Inc Annual Shareholders Meeting
Biomarin Pharmaceutical Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Wednesday, May 22, 2024

Time (UTC)

17:00

Country

US

Event

Biomarin Pharmaceutical Inc Annual Shareholders Meeting
Biomarin Pharmaceutical Inc Annual Shareholders Meeting

Forecast

-

Previous

-
Monday, July 29, 2024

Time (UTC)

20:00

Country

US

Event

Q2 2024 Biomarin Pharmaceutical Inc Earnings Release
Q2 2024 Biomarin Pharmaceutical Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 2096.04 1846.28 1860.45 1704.05 1491.21
Revenue 2096.04 1846.28 1860.45 1704.05 1491.21
Cost of Revenue, Total 483.669 470.515 524.272 359.466 315.264
Gross Profit 1612.37 1375.76 1336.18 1344.58 1175.95
Total Operating Expense 1946.48 1928.62 1897.22 1804.51 1614.74
Selling/General/Admin. Expenses, Total 831.009 760.923 737.784 675.665 610.014
Research & Development 649.606 628.793 628.116 715.007 696.328
Depreciation / Amortization 62.8 61.9 62.2 53.5 30.3
Interest Expense (Income) - Net Operating -1.548 -0.115 5.259 -5.661
Unusual Expense (Income) -85 0 -59.495 -25 -50
Other Operating Expenses, Total 4.393 8.033 4.458 20.608 18.491
Operating Income 149.562 -82.341 -36.765 -100.457 -123.524
Interest Income (Expense), Net Non-Operating 2.064 -4.855 -12.705 -1.299 -21.386
Other, Net -2.05 11.846 7.148 6.945 2.205
Net Income Before Taxes 149.576 -75.35 -42.322 -94.811 -142.705
Net Income After Taxes 141.561 -68 4.561 -23.848 -77.211
Net Income Before Extra. Items 141.561 -68 4.561 -23.848 -77.211
Net Income 141.561 -64.08 859.1 -23.848 -77.211
Income Available to Common Excl. Extra. Items 141.561 -68 4.561 -23.848 -77.211
Income Available to Common Incl. Extra. Items 141.561 -64.08 859.1 -23.848 -77.211
Diluted Net Income 141.561 -64.08 859.1 -23.848 -77.211
Diluted Weighted Average Shares 188.963 182.852 191.678 179.039 177.061
Diluted EPS Excluding Extraordinary Items 0.74915 -0.37189 0.0238 -0.1332 -0.43607
Diluted Normalized EPS 0.32343 -0.37189 -0.17796 -0.22396 -0.61962
Total Extraordinary Items 3.92 854.539 0
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 595.275 596.415 537.538 505.344 533.798
Revenue 595.275 596.415 537.538 505.344 533.798
Cost of Revenue, Total 128.082 126.549 127.29 116.288 123.126
Gross Profit 467.193 469.866 410.248 389.056 410.672
Total Operating Expense 536.405 537.068 562.038 507.761 494.646
Selling/General/Admin. Expenses, Total 215.336 223.003 245.739 216.816 196.835
Research & Development 177.363 171.846 172.751 157.829 158.19
Depreciation / Amortization 15.6 15.7 15.7 15.9 15.6
Unusual Expense (Income) 0 0 0 0 0
Other Operating Expenses, Total 0.024 -0.03 0.558 0.928 0.895
Operating Income 58.87 59.347 -24.5 -2.417 39.152
Interest Income (Expense), Net Non-Operating 8.857 8.24 5.084 0.32 -1.354
Other, Net 3.083 -10.83 1.858 0.193 -2.947
Net Income Before Taxes 70.81 56.757 -17.558 -1.904 34.851
Net Income After Taxes 56.04 50.852 -0.249 -6.652 27.664
Net Income Before Extra. Items 56.04 50.852 -0.249 -6.652 27.664
Net Income 56.04 50.852 -0.249 -6.652 27.664
Income Available to Common Excl. Extra. Items 56.04 50.852 -0.249 -6.652 27.664
Income Available to Common Incl. Extra. Items 56.04 50.852 -0.249 -6.652 27.664
Diluted Net Income 56.04 50.852 -0.249 -6.652 27.664
Diluted Weighted Average Shares 194.998 194.363 186.037 185.597 187.448
Diluted EPS Excluding Extraordinary Items 0.28739 0.26163 -0.00134 -0.03584 0.14758
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS 0.28739 0.26163 -0.00134 -0.03584 0.14758
Total Extraordinary Items
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 2751.46 2274.39 2342.22 1942.14 2056.22
Cash and Short Term Investments 1291.54 1013.88 1065.39 753.807 1084.31
Cash & Equivalents 724.531 587.276 649.158 437.446 493.982
Short Term Investments 567.006 426.599 416.228 316.361 590.326
Total Receivables, Net 461.316 373.399 448.351 377.404 342.633
Accounts Receivable - Trade, Net 461.316 373.399 448.351 377.404 342.633
Total Inventory 894.083 776.669 698.548 680.275 530.871
Other Current Assets, Total 104.521 110.442 129.934 130.657 98.403
Total Assets 6375.07 6003.33 5848.02 4690.04 4427.13
Property/Plant/Equipment, Total - Net 1114.32 1081.88 1089.58 1070.3 948.682
Property/Plant/Equipment, Total - Gross 1916.47 1802.45 1725.18 1619.4 1421.32
Accumulated Depreciation, Total -802.145 -720.574 -635.595 -549.1 -472.635
Goodwill, Net 196.199 196.199 196.199 197.039 197.039
Intangibles, Net 338.569 388.652 417.271 456.58 491.808
Long Term Investments 333.835 507.793 285.473 411.978 235.864
Other Long Term Assets, Total 1640.69 1554.42 1517.28 611.997 497.52
Total Current Liabilities 588.884 539.822 492.548 932.503 523.241
Payable/Accrued 231.238 193.003 191.429 240.981 208.119
Accrued Expenses 317.834 277.059 266.254 287.878 213.03
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 2.287 2.266 2.865 365.131 0
Other Current Liabilities, Total 37.525 67.494 32 38.513 102.092
Total Liabilities 1771.92 1732.58 1742.02 1567.66 1459.19
Total Long Term Debt 1083.2 1081.04 1079.15 492.946 830.417
Long Term Debt 1083.02 1079.08 1075.15 486.238 830.417
Deferred Income Tax
Other Liabilities, Total 99.831 111.726 170.319 142.209 105.53
Total Equity 4603.16 4270.74 4106 3122.38 2967.94
Common Stock 0.186 0.184 0.182 0.18 0.178
Additional Paid-In Capital 5404.9 5191.5 4993.41 4832.71 4669.93
Retained Earnings (Accumulated Deficit) -789.199 -925.689 -861.609 -1720.71 -1694.13
Other Equity, Total -0.633 6.116 -29.867 6.638 -6.113
Total Liabilities & Shareholders’ Equity 6375.07 6003.33 5848.02 4690.04 4427.13
Total Common Shares Outstanding 186.251 183.913 181.741 179.838 178.253
Unrealized Gain (Loss) -12.093 -1.373 3.889 3.565 -1.917
Capital Lease Obligations 0.184 1.96 4.006 6.708
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 2955.31 2950.12 2842.1 2751.46 2682.7
Cash and Short Term Investments 1125.84 1170.96 1152.09 1291.54 1273.77
Cash & Equivalents 785.414 694.381 580.074 724.531 761.515
Short Term Investments 340.431 476.577 572.017 567.006 512.253
Total Receivables, Net 572.498 610.222 597.913 461.316 419.622
Accounts Receivable - Trade, Net 572.498 610.222 597.913 461.316 419.622
Total Inventory 1032.16 975.546 918.921 894.083 839.46
Other Current Assets, Total 224.806 193.391 173.18 104.521 149.851
Total Assets 6758.16 6563.17 6433.69 6375.07 6264.04
Property/Plant/Equipment, Total - Net 1067.16 1067.28 1068.14 1114.32 1051.82
Property/Plant/Equipment, Total - Gross 1918.61 1896.45 1875.09 1916.47 1834.22
Accumulated Depreciation, Total -851.453 -829.177 -806.944 -802.145 -782.399
Goodwill, Net 196.199 196.199 196.199 196.199 196.199
Intangibles, Net 302.476 310.343 325.989 338.569 354.024
Long Term Investments 548.002 385.777 340.635 333.835 372.302
Other Long Term Assets, Total 1689.02 1653.46 1660.62 1640.69 1606.99
Total Current Liabilities 1163.22 597.231 598.231 588.884 521.02
Payable/Accrued 301.369 277.944 264.778 231.238 207.165
Accrued Expenses 350.452 291.027 307.568 317.834 264.051
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 18.004 28.26 25.885 37.525 49.804
Total Liabilities 1861.27 1780.34 1774.65 1771.92 1695.53
Total Long Term Debt 592.586 1084.99 1084.01 1083.2 1082.03
Long Term Debt 592.586 1084.99 1084.01 1083.02 1082.03
Other Liabilities, Total 105.457 98.12 92.415 99.831 92.473
Total Equity 4896.9 4782.83 4659.04 4603.16 4568.51
Common Stock 0.188 0.188 0.188 0.186 0.186
Additional Paid-In Capital 5542.77 5493.96 5417.87 5404.9 5335.85
Retained Earnings (Accumulated Deficit) -641.929 -682.307 -738.347 -789.199 -788.949
Unrealized Gain (Loss) -7.328 -8.582 -8.075 -12.093 -15.12
Other Equity, Total 3.192 -20.428 -12.596 -0.633 36.544
Total Liabilities & Shareholders’ Equity 6758.16 6563.17 6433.69 6375.07 6264.04
Total Common Shares Outstanding 188.339 188.152 187.601 186.251 185.824
Current Port. of LT Debt/Capital Leases 493.398 2.287
Capital Lease Obligations 0.184
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 141.561 -64.08 859.1 -23.848 -77.211
Cash From Operating Activities 175.902 304.536 85.365 48.262 20.208
Cash From Operating Activities 101.969 108.039 105.172 105.3 95.671
Deferred Taxes -52.087 -15.608 -888.907 -82.76 -68.378
Non-Cash Items 80.842 210.151 234.417 150.662 119.546
Cash Taxes Paid 54.372 18.153 8.977 9.726 16.676
Cash Interest Paid 10.281 10.395 12.178 8.552 11.623
Changes in Working Capital -96.383 66.034 -224.417 -101.092 -49.42
Cash From Investing Activities -20.029 -366.313 -53.621 -31.026 264.351
Capital Expenditures -131.54 -119.225 -137.519 -163.406 -144.62
Other Investing Cash Flow Items, Total 111.511 -247.088 83.898 132.38 408.971
Cash From Financing Activities -18.65 -0.048 181.118 -74.674 -388.007
Financing Cash Flow Items -85.378 -46.203 -44.638 -101.198 -80.542
Issuance (Retirement) of Stock, Net 69.333 49.194 21.913 31.611 67.488
Foreign Exchange Effects 0.032 -0.057 -1.15 0.902 -0.598
Net Change in Cash 137.255 -61.882 211.712 -56.536 -104.046
Issuance (Retirement) of Debt, Net -2.605 -3.039 203.843 -5.087 -374.953
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line 50.852 141.561 141.81 148.462 120.798
Cash From Operating Activities -73.932 175.902 169.116 10.795 -45.431
Cash From Operating Activities 26.421 101.969 77.416 52.614 27.343
Deferred Taxes -6.36 -52.087 -0.743 3.455 4.8
Non-Cash Items 71.797 80.842 33.872 -18.97 -61.68
Cash Taxes Paid 4.364 54.372 13.425 11.821 1.316
Cash Interest Paid 1.437 10.281 6.575 5.137 1.422
Changes in Working Capital -216.642 -96.383 -83.239 -174.766 -136.692
Cash From Investing Activities -30.012 -20.029 34.681 58.083 87.782
Capital Expenditures -24.766 -131.54 -95.181 -58.71 -30.675
Other Investing Cash Flow Items, Total -5.246 111.511 129.862 116.793 118.457
Cash From Financing Activities -40.742 -18.65 -29.519 -37.06 -25.28
Financing Cash Flow Items -60.897 -85.378 -71.75 -65.431 -32.949
Issuance (Retirement) of Stock, Net 21.169 69.333 43.866 29.493 8.235
Issuance (Retirement) of Debt, Net -1.014 -2.605 -1.635 -1.122 -0.566
Foreign Exchange Effects 0.229 0.032 -0.039 0.708 1.093
Net Change in Cash -144.457 137.255 174.239 32.526 18.164

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

BioMarin Company profile

About BioMarin Pharmaceutical Inc.

BioMarin Pharmaceutical Inc is a biotechnology company. The Company develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The Company’s portfolio consists of commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. The Company's commercial products include Aldurazyme (laronidase), Brineura (cerliponase alfa), Kuvan (sapropterin dihydrochloride), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Vimizim (elosulfase alpha) and Voxzogo (vosoritide). The Company's pipeline includes Valoctocogene Roxaparvovec for Severe Hemophilia A, Vosoritide for Achondroplasia, BMN 307 for Phenylketonuria (PKU) and BMN 331 for Hereditary Angioedema (HAE).

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, BioMarin Pharmaceutical Inc. revenues decreased 1% to $1.85B. Net loss before extraordinary items totaled $68M vs. income of $4.6M. Revenues reflect Kuvan1 segment decrease of 38% to $285.8M, Naglazyme1 segment decrease of 3% to $380.4M, United States segment decrease of 28% to $657.7M, Latin America segment decrease of 7% to $191.2M.

Equity composition

Common Stock $.001 Par, 04/11, 250M auth., 110,909,591 issd. Insiders own 0.26%. IPO 7/23/99, 4.5M shs. $13 by U.S. Bancorp Piper Jaffray. PO 12/01, 8,050,000 shs. @ $12 by UBS Warburg. 5/01, private placement 4,763,712 shares @ $9.45. PO 2/03, 7.5M shs @ $10 by UBS Warburg. PO 3/06 10,350,000 shs. @ $13/sh.

Industry: Biopharmaceuticals

105 Digital Dr
NOVATO
CALIFORNIA 94949
US

Income Statement

  • Annual
  • Quarterly

News

Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported

Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.

07:56, 17 April 2024

US Earnings Season : JP Morgan, Citigroup, Wells Fargo

The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.

16:03, 11 April 2024

Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues

The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.

09:22, 11 April 2024

US CPI Preview: US inflation expected to grind lower amid fears about sticky prices

US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).

15:11, 9 April 2024

How escalating geopolitical tensions are impacting oil markets

The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.

13:34, 4 April 2024

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

People also watch

ETH/USD

3,147.60 Price
-0.470% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 6.00

US100

17,096.70 Price
+0.390% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 1.8

BTC/USD

64,818.75 Price
-0.010% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

XRP/USD

0.53 Price
-0.450% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 610,000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading